Spark Therapeutics has announced that the first participant has been dosed in phase 1/2 study of investigational gene therapy for Late-Onset Pompe Disease.
To read the full press release click here: https://sparktx.com/press_releases/first-patient-dosed-pompe/
Disclaimer: The IPA does not endorse any of the products, medications, treatments or information reported herein. Articles on the IPA web pages are intended for informational purposes, only. We strongly advise that you discuss all medications, treatments, and/or products with your physician.